Sample Size Efficiency of 4-Period, 2-Seq, 2-Formulation Design [RSABE / ABEL]

posted by Sereng  – USA, 2022-01-28 22:40 (841 d 16:27 ago) – Posting: # 22759
Views: 1,732

❝ Can you post a link to the guidance?


Hi Helmut, many thanks for your response. Below are the PSG links, one PSG asks you to refer to the second, although the first one may have the information (Sorry, I don't know how to attach the document here). I look forward to your guidance. Regards

https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levothyroxine_Sodium%20capsules_NDA%20021924_RC%20Oct%202018.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/psg/Warfarin_Sodium_tab_09218_RC12-12.pdf


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
24 visitors (0 registered, 24 guests [including 6 identified bots]).
Forum time: 16:08 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5